Pfizer

Latest Pfizer Items
  • Pfizer recalls 28 lots of birth control pills

    Pfizer Inc. is recalling 1 million packets of birth control pills after uncovering a packaging error that could leave women with an inadequate dose of the hormone-based drugs and raise the risk that they will get pregnant accidentally.


  • Pfizer recalls 1M birth control packs after mixup

    Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose.


  • Pfizer recalls 1M birth control packs after mix-up

    Birth control pills are known to be nearly 100 percent effective when taken properly, but a recall of the drugs could send a shudder through women of childbearing age.


  • Pfizer recalls 28 lots of birth control pills

    Pfizer Inc. is recalling 1 million packets of birth control pills after uncovering a packaging error that could leave women with an inadequate dose of the hormone-based drugs and raise the risk that they will get pregnant accidentally.


  • EU court denies Viaguara trademark

    A European Union high court ruled on Wednesday that the name Viaguara cannot be registered as an EU trademark for energy and alcoholic drinks because it is too similar to the impotence pill Viagra.


  • FDA clears Pfizer vaccine for adults over 50

    Federal regulators have approved a vaccine for adults age 50 and older to prevent pneumococcal disease, including the most common type of pneumonia.


  • HOWARD: Expensive innovation is only path to cheap Lipitor

    Last month, Pfizer's cholesterol-fighting drug Lipitor, the world's best-selling medication, saw the expiration of its patent protection, thus opening the market to generic competition. Within just the past two weeks, Pfizer has lost nearly 50 percent of the market to atorvastatin (the generic version of Lipitor), a figure that probably will rise sharply over the next several months. But instead of cheering on the virtuous cycle of innovation, competition and consumer benefits that this represents, policymakers have slammed Pfizer for slashing the price of its own drug to compete with cheaper generics.


  • Pfizer manuevers to shield Lipitor from generics

    Pfizer is getting creative to preserve Lipitor's billions in sales as the cholesterol drug gets generic competition in the U.S. market.


  • Pfizer maneuvers to protect Lipitor from generics

    Lipitor is so valuable that Pfizer is practically paying people to keep taking its blockbuster cholesterol medicine after generic competition hits the U.S. market this week.


Happening Now